Capricor Therapeutics (CAPR) Common Equity (2010 - 2026)

Capricor Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $278.7 million for Q1 2026.

• On a quarterly basis, Common Equity rose 118.34% year-over-year to $278.7 million in Q1 2026; TTM through Mar 2026 was $278.7 million, a 118.34% increase from a year earlier, with the FY2025 full-year figure at $305.8 million, up 110.22% from the prior year.
• Common Equity slipped to $278.7 million in Q1 2026 per CAPR's latest filing, from $305.8 million in the prior quarter.
• Across five years, Common Equity topped out at $305.8 million in Q4 2025 and bottomed at -$1.8 million in Q3 2023.
• The 5-year median for Common Equity is $22.6 million (2023), against an average of $73.2 million.
• Across the five-year window, Common Equity sank 111.59% in 2023 and jumped 3918.69% in 2024, its largest moves.
• Year by year, Common Equity stood at $11.8 million in 2022, then surged by 91.76% to $22.6 million in 2023, then surged by 543.6% to $145.5 million in 2024, then soared by 110.22% to $305.8 million in 2025, then declined by 8.86% to $278.7 million in 2026.
• Per Business Quant, the three latest CAPR Common Equity figures stand at $278.7 million (Q1 2026), $305.8 million (Q4 2025), and $83.9 million (Q3 2025).